Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Background Darolutamide is a potent androgen-receptor inhibitor that has been associated
with increased overall survival among patients with nonmetastatic, castration-resistant …

The microbiota comprises the microorganisms that live in close contact with the host, with
mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence …

PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

Background The optimal timing of radiotherapy after radical prostatectomy for prostate
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …

Background In the interim analyses of the LATITUDE study, the addition of abiraterone
acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant …